Company
Leading the Korean pharmaceutical industry
The dawn of legendary boldness and creativity Jung-Jin Seo, the company chairman, first founded Nexol in 2000 to examine diverse business opportunities. Seo established Celltrion in 2002 and began to research the resources for production facilities for biopharmaceuticals.
- Oct. 2001
- Signed the MOU on the creation of a joint venture company
- Feb. 2002
- Foundation of Celltrion
Solidifying The Basis for Growth
From 2003 to 2008, Celltrion continued to grow and consolidate its basis for pioneering uncharted territories and achieving growth.
The company conquered the numerous challenges it encountered in the process.
- Jun. 2005
- Supply agreement with BMS(Bristol-Myers Squibb)
- Jul. 2005
- Mechanical completion of Plant 1(50,000L)
- Dec. 2007
- Plant 1 receives cGMP facility approval by the US FDA
- Aug. 2008
- Initial Public Offering(IPO)
Opening the Era of Biosimilars
In May 2013, the world’s first antibody biosimilar, Remsima, was approved by the EMA, signaling the start of Celltrion’s global expansion.
The company established its second plant, further augmenting its production capacity, to ensure a stable supply around the world.
- May. 2010
- Secured significant investment from
Temasek Holdings, Singapore - Oct. 2011
- Mechanical completion of Plant 2(90,000L)
- Jul.2012
- Remsima is approved by Korea (MFDS)
- Apr. 2013
- Begins global clinical trial of CT-P27
- Aug. 2013
- Remsima is approved by Europe (EMA)
- Jan. 2014
- Herzuma is approved by Korea (MFDS)
- Feb. 2014
- Begins clinical trial phase 2a of CT-P27
Securing A Path of Accelerated Growth
In 2016, Celltrion also obtained approval by the FDA on the distribution of Remsima in the United States, thereby gaining stability in the land of new opportunities.
Celltrion continues to lead the development of innovative treatments and technologies, including new drugs, vaccines, and biobetters, transforming itself into a world-renowned provider of a comprehensive range of biotechnology and engineering solutions.
- Mar. 2015
- Introduced a new management system
with professional executives. - Jun. 2015
- Plant 1 and Plant 2 receive approval from the FDA
of US. on all cGMP manufacturing facilities
- Apr. 2016
- Remsima is approved by US (FDA)
- Oct. 2016
- Reached KRW 1 trillion in cumulative Remsima exports
- Nov. 2016
- Truxima is approved by Korea (MFDS)
Remsima begins sales in US - Dec. 2016
- Begins clinical trial phase 2b of CT-P27
- Feb. 2017
- Truxima is approved by Europe (EMA)
- Jul. 2017
- Begins clinical trial phase 1 of CT-P16
- Feb. 2018
- Listed on KOSPI
Herzuma is approved by Europe (EMA) - May. 2018
- Signed an agreement with Yonsei University Health
System on the joint development and licensing-in
of treatment for ischemic strokes - Aug. 2018
- Begins clinical trial phase 1ㆍ3 of CT-P17
Begins clinical trial phase 3 of CT-P16 - Sep. 2018
- Signed an agreement with Emory University on
supporting the research and development
of a new drug for atherosclerosis - Nov. 2018
- Temixys is approved by US (FDA)
Truxima is approved by US (FDA) - Dec. 2018
- Herzuma is approved by US (FDA)
Designated as a long-term supplier for the international
HIV treatment procurement prog
- Jan. 2019
- Filed global patent application on RemsimaSC
- Mar. 2019
- Signed an exclusive distribution agreement on CT-G20,
a treatment for hypertrophic cardiomyopathy, in Japan - Apr. 2019
- Signed an agreement with iProgen Biotech on the joint
development of a new ADC drug based on ADED platform
Linezolid is approved by US (FDA) - May. 2019
- Mehcanical completion of the expansion of Plant 1
(additional 50,000 L) - Nov.2019
- RemsimaSC is approved by Europe (EMA)
- Feb. 2020
- Reached KRW 1 trillion in annual sales
RemsimaSC is approved by Korea (MFDS) - Mar. 2020
- Application for approval of CT-P17 is submitted in the EMA
- May. 2020
- Selected for national projects to develop MERS and COVID-19 antiviral treatment pipelines
- Jun. 2020
- Selected for national project to develop pen-type insulin biosimilar
Acquired Primary Care product assets for Asia Pacific markets from Takeda Ltd. - Aug. 2020
- Herzuma earned WHO Prequalification status
- Sep. 2020
- Begins clinical trial phase 2ㆍ3 of CT-P59
- Feb. 2021
- Yuflyma is approved by Europe (EMA)
- Sep. 2021
- Regkirona is approved by Korea (MFDS)
- Oct. 2021
- Yuflyma is approved by Korea (MFDS)
- Nov. 2021
- Regkirona is approved by Europe (EMA)
- Aug. 2022
- Vegzelma is approved by Europe (EMA)
- Sep. 2022
- Vegzelma is approved by US (FDA)
Vegzelma is approved by Korea (MFDS) - May. 2023
- Yuflyma is approved by US (FDA)
